Last reviewed · How we verify
RSV vaccine candidate
At a glance
| Generic name | RSV vaccine candidate |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate (PHASE1, PHASE2)
- Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older (PHASE2)
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older (PHASE1)
- Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults (PHASE1)
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (PHASE1, PHASE2)
- Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years (PHASE1)
- A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (PHASE1)
- Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV vaccine candidate CI brief — competitive landscape report
- RSV vaccine candidate updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI